Lopinavir

The World Health Organisation on Saturday has stopped its trials of the malaria drug hydroxychloroquine and combination of HIV drug lopinavir/ritonavir for the treatment of hospitalised COVID-19 patients after they failed to reduce the death rate, Al Jazeera reported.

The World Health Organization is looking at interim data from its large multi-country trial of the combination of HIV drugs Lopinavir and Ritonavir to treat COVID-19 patients, the UN agency's chief scientist Soumya Swaminathan said on Thursday.

The Union Health Ministry has recommended use of anti-HIV drug combinations Lopinavir and Ritonavir on a case-to-case basis depending upon the severity of the condition of a patient having coronavirus infection.

Cipla MD & Global CEO Subhanu Saxena said: "This innovative way of drug delivery through oral pellets for some of society's youngest AIDS sufferers reiterates our commitment to provide access to life saving medicines in the fight against HIV/ AIDS."

What serves as one of the biggest threats against people living with HIV AIDS is multinational drug companies, producing lifesaving drugs, pushing for patents so generic companies cannot produce them at much lower prices. However, in a much needed relief to Indian pharmaceutical companies as well as patients, India rejected a patent application fil...

The World Health Organisation on Saturday has stopped its trials of the malaria drug hydroxychloroquine and combination of HIV drug lopinavir/ritonavir for the treatment of hospitalised COVID-19 patients after they failed to reduce the death rate, Al Jazeera reported.

The World Health Organization is looking at interim data from its large multi-country trial of the combination of HIV drugs Lopinavir and Ritonavir to treat COVID-19 patients, the UN agency's chief scientist Soumya Swaminathan said on Thursday.

The Union Health Ministry has recommended use of anti-HIV drug combinations Lopinavir and Ritonavir on a case-to-case basis depending upon the severity of the condition of a patient having coronavirus infection.

Cipla MD & Global CEO Subhanu Saxena said: "This innovative way of drug delivery through oral pellets for some of society's youngest AIDS sufferers reiterates our commitment to provide access to life saving medicines in the fight against HIV/ AIDS."

What serves as one of the biggest threats against people living with HIV AIDS is multinational drug companies, producing lifesaving drugs, pushing for patents so generic companies cannot produce them at much lower prices. However, in a much needed relief to Indian pharmaceutical companies as well as patients, India rejected a patent application fil...